Database Query Results : , , EMT

EMT, Epithelial-Mesenchymal Transition: Click to Expand ⟱
Source:
Type:
Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin.
EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin).
EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis.
Scientific Papers found: Click to Expand⟱
1094- ACNs,    Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT.
- in-vitro, GBM, U87MG
EMT↓,
2662- AL,    Allicin inhibits tubular epithelial-myofibroblast transdifferentiation under high glucose conditions in vitro
- in-vitro, Nor, HK-2
*α-SMA↓, *Vim↓, *COL1↓, *E-cadherin↑, *TGF-β1↓, *p‑ERK↓, *EMT↓,
278- ALA,    The Multifaceted Role of Alpha-Lipoic Acid in Cancer Prevention, Occurrence, and Treatment
- Review, NA, NA
ROS↑, NRF2↑, Inflam↓, frataxin↑, *BioAv↓, ChemoSen↑, Hif1a↓, eff↑, FAK↓, ITGB1↓, MMP2↓, MMP9↓, EMT↓, Snail↓, Vim↓, Zeb1↓, P53↑, MGMT↓, Mcl-1↓, Bcl-xL↓, Bcl-2↓, survivin↓, Casp3↑, Casp9↑, BAX↑, p‑Akt↓, GSK‐3β↓, *antiOx↑, *ROS↓, selectivity↑, angioG↓, MMPs↓, NF-kB↓, ITGB3↓, NADPH↓,
276- ALA,    Alpha lipoic acid diminishes migration and invasion in hepatocellular carcinoma cells through an AMPK-p53 axis
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B
P53↑, EMT↓, AMPK↑, cycD1↓, TumCMig↓,
284- ALA,    Lipoic acid a multi-level molecular inhibitor of tumorigenesis
- Review, Var, NA
EMT↓, TumMeta↓,
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
1095- Api,    Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway
- Analysis, Colon, NA
Snail↓, EMT↓, NF-kB↓,
210- Api,    Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer
- in-vitro, Pca, DU145
EMT↓, E-cadherin↑, Snail↓, Vim↓,
244- Api,    Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma
- in-vivo, Melanoma, B16-F10 - in-vivo, Melanoma, A375 - in-vivo, Melanoma, G361
STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, E-cadherin↑, N-cadherin↓, EMT↓,
1547- Api,    Apigenin: Molecular Mechanisms and Therapeutic Potential against Cancer Spreading
- Review, NA, NA
angioG↓, EMT↓, CSCs↓, TumCCA↑, Dose∅, ROS↑, MMP↓, Catalase↓, GSH↓, PI3K↓, Akt↓, NF-kB↓, OCT4↓, Nanog↓, SIRT3↓, SIRT6↓, eff↑, eff↑, Cyt‑c↑, Bax:Bcl2↑, p‑GSK‐3β↓, FOXO3↑, p‑STAT3↓, MMP2↓, MMP9↓, COX2↓, MMPs↓, NRF2↓, HDAC↓, Telomerase↓, eff↑, eff↑, eff↑, eff↑, eff↑, XIAP↓, survivin↓, CK2↓, HSP90↓, Hif1a↓, FAK↓, EMT↓,
1548- Api,    A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms
- Review, Colon, NA
*BioAv↓, *Half-Life∅, selectivity↑, *toxicity↓, Wnt/(β-catenin)↓, P53↑, P21↑, PI3K↓, Akt↓, mTOR↓, TumCCA↑, TumCI↓, TumCMig↓, STAT3↓, PKM2↓, EMT↓, cl‑PARP↑, Casp3↑, Bax:Bcl2↑, VEGF↓, Hif1a↓, Dose∅, GLUT1↓, GlucoseCon↓,
3382- ART/DHA,    Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
- Review, Var, NA
AntiCan↑, toxicity↑, Ferroptosis↑, ROS↑, TumCCA↑, BioAv↝, eff↝, Half-Life↓, Ferritin↓, GPx4↓, NADPH↓, GSH↓, BAX↑, Cyt‑c↑, cl‑Casp3↑, VEGF↓, IL8↓, COX2↓, MMP9↓, E-cadherin↑, MMP2↓, NF-kB↓, p16↑, CDK4↓, cycD1↓, p62↓, LC3II↑, EMT↓, CSCs↓, Wnt↓, β-catenin/ZEB1↓, uPA↓, TumAuto↑, angioG↓, ChemoSen↑,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2↓, JNK↑, Beclin-1↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2↓, MMP9↓,
1099- ART/DHA,    Dihydroartemisinin inhibits IL-6-induced epithelial–mesenchymal transition in laryngeal squamous cell carcinoma via the miR-130b-3p/STAT3/β-catenin signaling pathway
- in-vitro, NA, NA
EMT↓, TumCI↓, STAT3↓, β-catenin/ZEB1↓,
1097- AS,    Astragalus Inhibits Epithelial-to-Mesenchymal Transition of Peritoneal Mesothelial Cells by Down-Regulating β-Catenin
- in-vitro, Nor, HMrSV5 - in-vivo, NA, NA
*EMT↓, *E-cadherin↑, *α-SMA↓, *Vim↓, *β-catenin/ZEB1↓, *Smad7↑,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
MAPK↑, p38↑, BAX↑, BIM↑, CHOP↑, ROS↑, DR5↑, Apoptosis↑, Ferroptosis↑, GPx4↓, BioAv↝, HSP90↓, RET↓, E6↓, E7↓, Akt↓, cMET↓, Glycolysis↓, TCA↓, NOTCH1↓, STAT3↓, AP-1↓, PI3K↓, eIF2α↓, HO-1↑, TumCCA↑, CDK1↓, *hepatoP↑, *GSH↑, *NRF2↑, Wnt↓, EMT↓, uPA↓, CSCs↓, Nanog↓, SOX2↓, CD44↓, lactateProd↓, Iron↑, NF-kB↓,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
TumCCA↑, H3↑, P21↑, cycA1↓, CycB↓, cycE↓, CDC2↓, CHK1↓, Chk2↓, p38↑, MAPK↑, E6↓, E7↓, P53↑, Akt↓, FOXO3↑, ROS↑, γH2AX↑, MMP↓, mitResp↓, eff↑, TumCD↑, Mcl-1↓, ER Stress↑, ATF4↑, ATF3↑, CHOP↑, NOTCH↓, NF-kB↓, Bcl-2↓, STAT3↓, CDK1↓, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, Cyt‑c↑, eff↑, CDK4↓, p‑RB1↓, PARP↑, cl‑Casp3↑, cl‑Casp9↑, NRF2↑, ER-α36↓, LDHA↓, lipid-P↑, AP-1↓, COX2↓, RenoP↑, PDGFR-BB↓, SIRT3↑, MMP2↓, MMP9↓, NADPH↑, NQO1↑, GSR↑, HO-1↑, *SOD2↑, *Prx↑, *Casp3?, eff↑, Snail↓, Slug↓, Vim↓, CSCs↓, HEY1↓, MMPs↓, VEGF↓, uPA↓, *toxicity↓, CDK2↓, CDK4↓, HSP90↓,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoP↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
3172- Ash,    Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis
- in-vitro, HCC, HepG2 - in-vitro, Nor, HL7702
Keap1↑, NRF2↓, EMT↓, TumCP↓, TumCI↓, selectivity↑, *toxicity↓, ROS↑, MDA↑, GSH↓, Ferroptosis↑,
999- Ba,    Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer
- in-vitro, Lung, H460
TumCP↓, p‑PDK1↓, p‑Akt↓, EMT↓, E-cadherin↑, Vim↓,
2630- Ba,    Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice
- in-vivo, Nor, NA
*RenoP↑, *uricA↓, *ROS↓, EMT↓,
2290- Ba,    Research Progress of Scutellaria baicalensis in the Treatment of Gastrointestinal Cancer
- Review, GI, NA
p‑mTOR↓, p‑Akt↓, p‑IKKα↓, NF-kB↓, PI3K↓, Akt↓, ROCK1↓, GSK‐3β↓, CycB↓, cycD1↓, cycA1↑, CDK4↓, P53↑, P21↑, TumCCA↑, MMP2↓, MMP9↓, EMT↓, Hif1a↓, Shh↓, PD-L1↓, STAT3↓, IL1β↓, IL2↓, IL6↓, PKM2↓, HDAC10↓, P-gp↓, Bcl-xL↓, eff↓, BioAv↓, BioAv↑,
2473- BA,    Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B - in-vitro, Lung, H460
EMT↓, PDK1↓, Akt↓, TumCMig↓, E-cadherin↑, Vim↓,
1392- BBR,    Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress
- in-vitro, GC, AGS - in-vitro, GC, MKN45
TumCG↓, TumCMig↓, ROS↑, MDA↑, SOD↓, NRF2↓, HO-1↓, Hif1a↓, EMT↓, Snail↓, Vim↓,
1102- BBR,    Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells
- in-vitro, Melanoma, B16-BL6
TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1↓, cycE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
2686- BBR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Nor, NA
Inflam↓, IL6↓, MCP1↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27↑, CDK2↓, CDK4↓, cycD1↓, cycE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
1031- BCA,    Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer
- vitro+vivo, CRC, HCT116 - vitro+vivo, CRC, SW-620
PD-L1↓, TumCG↓, Zeb1↓, E-cadherin↑, N-cadherin↓, EMT↓,
2743- BetA,    Betulinic acid and the pharmacological effects of tumor suppression
- Review, Var, NA
ROS↓, MMP↓, Cyt‑c↑, Apoptosis↑, TumCCA↑, Sp1/3/4↓, STAT3↓, NF-kB↓, EMT↓, TOP1↓, MAPK↑, p38↑, JNK↑, Casp↑, Bcl-2↓, BAX↑, VEGF↓, LAMs↓,
2741- BetA,    Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress
- in-vitro, GC, SNU16 - in-vitro, GC, NCI-N87 - in-vivo, NA, NA
TumCG↓, TumCMig↓, TumCI↓, N-cadherin↓, E-cadherin↑, EMT↓, Ki-67↓, MMP2↓,
2729- BetA,    Betulinic acid in the treatment of tumour diseases: Application and research progress
- Review, Var, NA
ChemoSen↑, mt-ROS↑, STAT3↓, NF-kB↓, selectivity↑, *toxicity↓, eff↑, GRP78/BiP↑, MMP2↓, P90RSK↓, TumCI↓, EMT↓, MALAT1↓, Glycolysis↓, AMPK↑, Sp1/3/4↓, Hif1a↓, angioG↓, NF-kB↑, NF-kB↓, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, RadioS↑, PERK↑, CHOP↑, *toxicity↓,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
2731- BetA,    Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives
- Review, GBM, NA - Review, Park, NA - Review, AD, NA
BBB↑, *GSH↑, *Catalase↑, *motorD↑, *neuroP↑, *cognitive↑, *ROS↓, *antiOx↑, *Inflam↓, MMP↓, STAT3↓, NF-kB↓, Sp1/3/4↓, TOP1↓, EMT↓, Hif1a↓, VEGF↓, ChemoSen↑, RadioS↑, BioAv↓,
733- Bor,    The analysis of boric acid effect on epithelial-mesenchymal transition of CD133 + CD117 + lung cancer stem cells
- in-vitro, Lung, NA
Snail↑, ITGB1↑, ITGA5↑, COL1A1↓, LAMA5↑, MMP3↓, Vim↓, E-cadherin↑, EMT↓, Zeb1↑,
1651- CA,  PBG,    Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer
- Review, Var, NA
Apoptosis↑, TumCCA↓, TumCMig↓, TumMeta↓, ChemoSen↑, eff↑, eff↑, eff↓, eff↝, Dose∅, AMPK↑, p62↓, LC3II↑, Ca+2↑, Bax:Bcl2↑, CDK4↑, CDK6↑, RB1↑, EMT↓, E-cadherin↑, Vim↓, β-catenin/ZEB1↓, NF-kB↓, angioG↑, VEGF↓, TSP-1↑, MMP9↓, MMP2↓, ChemoSen↑, eff↑, ROS↑, CSCs↓, Fas↑, P53↑, BAX↑, Casp↑, β-catenin/ZEB1↓, NDRG1↑, STAT3↓, MAPK↑, ERK↑, eff↑, eff↑, eff↑,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
1103- CBD,    Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway
- vitro+vivo, NA, NA
Apoptosis↑, TumCP↓, TumCMig↓, TumMeta↓, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, Hif1a↓, Wnt/(β-catenin)↓, AXIN1↑, TumVol↓, TumW↓,
1105- CEL,    Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis
- in-vitro, BC, NA
COX2↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓, miR-145↑, TGF-β↓, SMAD3↓,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1↓, hTERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1↓, hTERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1↓, hTERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
1107- CHr,    Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway
- in-vitro, BC, NA
TumCP↓, Apoptosis↑, MMP-10↓, E-cadherin↑, Vim↓, Snail↓, Slug↓, EMT↓,
16- CP,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, N-cadherin↓, E-cadherin↑, Snail↓,
140- CUR,    Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling
- in-vitro, Pca, PC3
CAFs/TAFs↓, EMT↓, ROS↓, CXCR4↓, IL6↓, MAOA↓, mTOR↓, HIF-1↓,
1108- CUR,    Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition
- Review, NA, NA
EMT↓,
433- CUR,    Curcumin Inhibits the Migration and Invasion of Non-Small-Cell Lung Cancer Cells Through Radiation-Induced Suppression of Epithelial-Mesenchymal Transition and Soluble E-Cadherin Expression
- in-vitro, Lung, A549
E-cadherin↓, Vim↓, Slug↓, N-cadherin↓, Snail↓, MMP9↓, EMT↓,
411- CUR,    Curcumin inhibits the invasion and metastasis of triple negative breast cancer via Hedgehog/Gli1 signaling pathway
- in-vitro, BC, MDA-MB-231
HH↓, EMT↓, Gli1↓,
464- CUR,    Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, TPC-1
TumCI↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, STAT3↓, miR-301a-3p↓, STAT↓, N-cadherin↓, Vim↓, Fibronectin↓, p‑JAK↓, p‑JAK2↓, p‑JAK3↓, p‑STAT1↓, p‑STAT2↓, E-cadherin↑,
470- CUR,    Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line
- in-vitro, Ovarian, SKOV3
Wnt/(β-catenin)↓, EMT↓, DNMT3A↓, cycD1↓, cMyc↓, Fibronectin↓, Vim↓, E-cadherin↑, SFRP5↑,
442- CUR,  5-FU,    Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress
- in-vitro, CRC, HCT116
Apoptosis↑, TumCP↓, TumCCA↑, TET1↑, NKD2↑, Wnt↓, EMT↓, Vim↑, E-cadherin↓, β-catenin/ZEB1↓, TCF↓, AXIN1↓,
443- CUR,    Reduced Caudal Type Homeobox 2 (CDX2) Promoter Methylation Is Associated with Curcumin’s Suppressive Effects on Epithelial-Mesenchymal Transition in Colorectal Cancer Cells
- in-vitro, CRC, SW480
DNMT1↓, DNMT3A↓, N-cadherin↓, Vim↓, Wnt↓, Snail↓, Twist↓, β-catenin/ZEB1↓, E-cadherin↑, EMT↓, CDX2↓,
447- CUR,  OXA,    Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway
- vitro+vivo, CRC, HCT116
p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
455- CUR,    Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin
- in-vitro, GC, SGC-7901
Shh↓, Gli1↓, Foxm1↓, β-catenin/ZEB1↓, TumCMig↓, Apoptosis↑, TumCCA↑, Wnt↓, EMT↓, E-cadherin↑, Vim↓,
478- CUR,    Curcumin decreases epithelial‑mesenchymal transition by a Pirin‑dependent mechanism in cervical cancer cells
- in-vitro, Cerv, SiHa
EMT↓, N-cadherin↓, Vim↓, Slug↓, Zeb1↓, PIR↓, Pirin↓, E-cadherin↑,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
2688- CUR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Var, NA - Review, AD, NA
*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↑, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, eff↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,
19- Deg,    Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1
HH↓, Gli1↓, PTCH1↓, Sufu↓, MMP2↓, MMP9↓, PI3K/Akt↓, HIF-1↓, VEGF↓, IKKα↓, NF-kB↓, EMT↓, AMPK↑, mTOR↓, survivin↓,
1109- DHA,    DHA inhibits Gremlin-1-induced epithelial-to-mesenchymal transition via ERK suppression in human breast cancer cells
- in-vitro, BC, NA
GREM1↓, TumCMig↓, p‑ERK↓, EMT↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
1607- EA,    Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions
- Review, GC, NA
STAT3↓, TumCP↓, Apoptosis↑, NF-kB↓, EMT↓, RadioS↑, antiOx↑, COX1↓, COX2↓, cMyc↓, Snail↓, Twist↓, MMP2↓, P90RSK↓, CDK8↓, PI3K↓, Akt↓, TumCCA↑, Casp8↑, PCNA↓, TGF-β↓, Shh↓, NOTCH↓, IL6↓, ALAT↓, ALP↓, AST↓, VEGF↓, P21↑, *toxicity∅,
1111- EDM,    Evodiamine exerts inhibitory roles in non‑small cell lung cancer cell A549 and its sub‑population of stem‑like cells
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓,
1072- EGCG,    Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways
- in-vitro, Thyroid, 8505C
EMT↓, TumCI↓, TumCMig↓, TGF-β↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓,
22- EGCG,    Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics
- in-vitro, PC, CD133+ - in-vitro, PC, CD44+ - in-vitro, PC, CD24+ - in-vitro, PC, ESA+
HH↓, Smo↓, PTCH1↓, PTCH2↓, Gli1↓, GLI2↓, Gli↓, Bcl-2↓, XIAP↓, Shh↓, EMT↓, survivin↓, Nanog↓, Casp3↑, Casp7↑,
685- EGCG,  CUR,  SFN,  RES,  GEN  The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein
- Analysis, NA, NA
Bcl-2↓, survivin↓, XIAP↓, EMT↓, Apoptosis↑, Nanog↓, cMyc↓, OCT4↓, Snail↓, Slug↓, Zeb1↓, TCF↓,
1322- EMD,    The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers
- Review, Var, NA
Apoptosis↑, TumCP↓, ROS↑, TumAuto↑, EMT↓, TGF-β↓, DNAdam↑, ER Stress↑, TumCCA↑, ATP↓, NF-kB↓, CYP1A1↑, STAC2↓, JAK↓, PI3K↓, Akt↓, MAPK↓, FASN↓, HER2/EBBR2↓, ChemoSen↑, eff↑, ChemoSen↑, angioG↓, VEGF↓, MMP2↓, eNOS↓, FOXD3↑, MMP9↓, TIMP1↑,
1247- EMD,    Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition
- vitro+vivo, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,
1246- EMD,    Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation
- in-vivo, BC, NA
TGF-β↓, EMT↓, CSCs↓,
1114- F,    The Potential Effect of Fucoidan on Inhibiting Epithelial-to-Mesenchymal Transition, Proliferation, and Increase in Apoptosis for Endometriosis Treatment: In Vivo and In Vitro Study
- vitro+vivo, NA, NA
tumCV↓, TumCMig↓, VEGF↓, EMT↓, Apoptosis↑,
1155- F,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
1112- FA,    Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition
- in-vitro, BC, MDA-MB-231 - in-vivo, BC, NA
tumCV↓, Apoptosis↑, AntiTum↑, TumMeta↓, EMT↓, TumVol↓, TumW↓,
1656- FA,    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
- Review, Var, NA
tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,
1113- FIS,    Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, Vim↓, N-cadherin↓, MMP2↓, CD44↓, CD133↓, β-catenin/ZEB1↓, NF-kB↓, EGFR↓, STAT3↓,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1↓, cycA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2829- FIS,    Fisetin: An anticancer perspective
- Review, Var, NA
TumCP↓, TumCI↓, TumCCA↑, TumCG↓, Apoptosis↑, cl‑PARP↑, PKCδ↓, ROS↓, ERK↓, NF-kB↓, survivin↓, ROS↑, PI3K↓, Akt↓, mTOR↓, MAPK↓, p38↓, HER2/EBBR2↓, EMT↓, PTEN↑, HO-1↑, NRF2↑, MMP2↓, MMP9↓, MMP↓, Casp8↑, Casp9↑, TRAILR↑, Cyt‑c↑, XIAP↓, P53↑, CDK2↓, CDK4↓, CDC25↓, CDC2↓, VEGF↓, DNAdam↑, TET1↓, CHOP↑, CD44↓, CD133↓, uPA↓,
2830- FIS,    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent
- Review, Var, NA
TumCG↓, angioG↓, *ROS↓, TumCMig↓, VEGF↓, MAPK↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, NRF2↑, HO-1↑, ROS↓, Inflam↓, ER Stress↑, ROS↑, TumCP↓, ChemoSen↑, PTEN↑, P53↑, Casp3↑, Casp8↑, Casp9↑, COX2↓, Wnt↓, EGFR↓, Mcl-1↓, survivin↓, IAP1↓, IAP2↓, PGE2↓, β-catenin/ZEB1↓, DR5↑, MMP2↓, MMP9↓, FAK↓, uPA↓, EMT↓, ERK↓, JNK↑, p38↑, PKCδ↓, BioAv↓, BioAv↑, BioAv↑,
2832- FIS,    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies
- Review, Var, NA
MMP↓, mtDam↑, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, Bak↑, BIM↑, Bcl-xL↓, Bcl-2↓, P53↑, ROS↑, AMPK↑, Casp9↑, Casp3↑, BID↑, AIF↑, Akt↓, mTOR↓, MAPK↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, P21↑, p27↑, cycD1↓, cycE↓, CDK2↓, CDK4↓, CDK6↓, TumMeta↓, uPA↓, E-cadherin↑, Vim↓, EMT↓, Twist↓, DNAdam↑, ROS↓, COX2↓, PGE2↓, HSF1↓, cFos↓, cJun↓, AP-1↓, Mcl-1↓, NF-kB↓, IRE1↑, ER Stress↑, ATF4↑, GRP78/BiP↑, MMP2↓, MMP9↓, TCF-4↓, MMP7↓, RadioS↑, TOP1↓, TOP2↓,
2839- FIS,    Dietary flavonoid fisetin for cancer prevention and treatment
- Review, Var, NA
DNAdam↑, ROS↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Cyt‑c↑, lipid-P↓, TumCG↓, TumCA↓, TumCMig↓, TumCI↓, uPA↓, ERK↓, MMP9↓, NF-kB↓, cFos↓, cJun↓, AP-1↓, TumCCA↑, AR↓, mTORC1↓, mTORC2↓, TSC2↑, EGF↓, TGF-β↓, EMT↓, P-gp↓, PI3K↓, Akt↓, mTOR↓, eff↑, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, ChemoSen↑, CDK2↓, CDK4↓, cycE↓, cycD1↓, P21↑, COX2↓, Wnt↓, EGFR↓, β-catenin/ZEB1↓, TCF-4↓, MMP7↓, RadioS↑, eff↑,
4027- FulvicA,    Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, MCF10
tumCV↓, selectivity↑, TGF-β↓, Twist↓, NOTCH1↓, CTNNB1↓, Src↓, E-cadherin↑, EMT↓, TumMeta↓, BioAv↑,
1115- GA,    Gallic acid alleviates gastric precancerous lesions through inhibition of epithelial mesenchymal transition via Wnt/β-catenin signaling pathway
- in-vivo, GC, GES-1
TumCP↓, TumCCA↑, Wnt/(β-catenin)↓, EMT↓,
814- GAR,  PacT,    Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model
- in-vivo, BC, NA
Apoptosis↑, TumCCA↑, EMT↓, TumCI↓,
800- GAR,    Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
EMT↓, MET↑, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↑, miR-200c↑, Let-7↑, p‑β-catenin/ZEB1↓, NF-kB↓,
1118- Ge,    Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway
- in-vitro, Bladder, T24 - in-vitro, Bladder, 5637
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Vim↓, Slug↓, E-cadherin↑, ZO-1↑, p‑SMAD2↓, p‑SMAD3↓, p‑Akt↓, p‑ERK↓, p‑p38↓,
1240- Ge,  PACs,    Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE2 Synthesis and Reversal of Epithelial-to-Mesenchymal Transition
- in-vitro, Melanoma, A375 - in-vitro, Melanoma, Hs294T
TumCMig↓, TumCI↓, COX2↓, PGE2↓, NF-kB↓, EMT↓, E-cadherin↑, Vim↓, Fibronectin↓, N-cadherin↓,
2998- GEN,    Cellular and Molecular Mechanisms Modulated by Genistein in Cancer
- Review, Var, NA
Hif1a↓, VEGF↓, PDGF↓, uPA↓, MMP2↓, MMP9↓, chemoP↑, TumCI↓, TumMeta↓, NF-kB↓, AP-1↓, IKKα↓, PI3K↓, Akt↓, EMT↓, CSCs↓,
1643- HCAs,    Mechanisms involved in the anticancer effects of sinapic acid
- Review, Var, NA
*BioAv↓, *toxicity↓, Dose∅, ROS⇅, ROS↑, Igs↑, TumCCA↑, TumAuto↑, eff↑, angioG↓, TumCI↓, TumMeta↓, EMT↓, Vim↓, MMP9↓, MMP2↓, Snail↓, E-cadherin↑, p‑Akt↓, GSK‐3β↓, TumCP↓, ChemoSen↑,
1120- HNK,    Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling
- vitro+vivo, RCC, NA
EMT↓, CSCs↓, TumCG↓, miR-141↑,
1119- HNK,    Honokiol inhibits epithelial—mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E‐cadherin axis
- vitro+vivo, BC, NA
EMT↓, MSCmark↓, EM↑, STAT3↓, Zeb1↓, E-cadherin↑,
2881- HNK,    Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis
- in-vitro, PC, PANC1
tumCV↓, Casp3↑, Apoptosis↑, TumCCA↑, TumCI↓, Mcl-1↓, EMT↓,
2882- HNK,    Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
- in-vitro, PC, PANC1
TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoP↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2884- HNK,    Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP
- in-vitro, Lung, A549 - in-vitro, Lung, H460
EMT↓, cFLIP↓, N-cadherin↓, Snail↓, p‑SMAD2↓, p‑SMAD3↓, IKKα↑, TumCMig↓, NA↑,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1↓, cycE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2866- HNK,    Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship
- Review, Var, NA
EMT↓, TumMeta↓, BioAv↑, BBB↑,
2877- HNK,    Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer
- in-vitro, GC, AGS
HDAC3↓, NF-kB↓, CEBPB↓, ER Stress↑, EMT↓, Wnt↓, β-catenin/ZEB1↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
1266- LE,    Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,
1122- LF,  MTX,    Lactoferrin Reverses Methotrexate Driven Epithelial Barrier Defect by Inhibiting TGF-β Mediated Epithelial to Mesenchymal Transition
- in-vivo, Colon, Caco-2
TGF-β↓, EMT↓,
1100- LT,    Luteolin, a flavonoid, as an anticancer agent: A review
- Review, NA, NA
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, ROS↑, ER Stress↑, mtDam↑, p‑eIF2α↝, p‑PERK↝, p‑CHOP↝, p‑ATF4↝, cl‑Casp12↝,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1↓, CycB↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2912- LT,    Luteolin: a flavonoid with a multifaceted anticancer potential
- Review, Var, NA
ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1↓, Hif1a↓, LC3II↑, Beclin-1↑,
1714- Lyco,    Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load
- in-vitro, Ovarian, OV-MZ-6 - in-vivo, NA, NA
ChemoSen↑, CA125↓, ITGA5↓, ITGB1↓, MMP9↓, FAK↓, EMT↓, MAPK↓, MMP9↓, antiOx↑, Ki-67↓, MAPK↓,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
2371- MET,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2377- MET,    Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,
2376- MET,    Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway
- in-vitro, Nor, NA
*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
1129- NarG,    Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity
- in-vitro, Pca, PC3
E-cadherin↓, Vim↓, Snail↓, Twist↓, EMT↓, uPA↓,
1673- PBG,    An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,
3257- PBG,    The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review
- Review, Var, NA
CDK4↓, CDK6↓, pRB↓, ROS↓, TumCCA↑, P21↑, PI3K↓, Akt↓, EMT↓, E-cadherin↑, Vim↓, *COX2↓, *MPO↓, *MDA↓, *TNF-α↓, *IL6↓, *Catalase↑, *SOD↑, *AST↓, *ALAT↓, *IL1β↓, *IL10↓, *GPx↓, *TLR4↓, *Sepsis↓, *IFN-γ↑, *GSH↑, *NRF2↑, *α-SMA↓, *TGF-β↓, *IL5↓, *IL6↓, *IL8↓, *PGE2↓, *NF-kB↓, *MMP9↓,
1258- PI,    Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer
- in-vivo, CRC, NA
COX2↓, IL6↓, EMT↓, β-catenin/ZEB1↓, Snail↓, Symptoms∅,
1256- PI,    Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
- in-vitro, adrenal, PHEO - in-vivo, NA, NA
Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,
1257- PI,    Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways
- ex-vivo, LiverDam, NA
*Fibronectin↓, *α-SMA↓, *COL1↓, *COL3A1↓, *TGF-β↓, *EMT↓, *MMP2↓, *α-SMA↓, *Smad7↑, *E-cadherin↑, *Vim↓, *hepatoP↑, *antiOx↑, *GSH↑, *ROS↓,
1059- PI,    Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, A549 - in-vitro, BC, MDA-MB-231 - in-vitro, Liver, HepG2
EMT↓, p‑ERK↓, p‑SMAD2↓,
1131- PI,    Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549
TumCG↓, tumCV↓, TumCMig↓, TumCI↓, MMP2↓, Slug↓, N-cadherin↓, β-catenin/ZEB1↓, SMAD3↓, E-cadherin↑, EMT↓,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24 - in-vivo, Bladder, NA
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB↓, cycD1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, NA↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2973- PL,    The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1
MMP2↓, MMP9↓, IL6↓, E-cadherin↑, ROS↑, EMT↓, Zeb1↓, Slug↓, TumMeta↓, selectivity↑, NA↑, GSH↓,
1236- PTS,    Pterostilbene inhibits the metastasis of TNBC via suppression of β-catenin-mediated epithelial to mesenchymal transition and stemness
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
TumMeta↓, EMT↓, E-cadherin↑, Zeb1↓, Snail↓, β-catenin/ZEB1↓, CD44↓, MMPs↓,
3374- QC,    Therapeutic effects of quercetin in oral cancer therapy: a systematic review of preclinical evidence focused on oxidative damage, apoptosis and anti-metastasis
- Review, Oral, NA - Review, AD, NA
α-SMA↓, α-SMA↑, TumCP↓, tumCV↓, TumVol↓, TumCI↓, TumMeta↓, TumCMig↓, ROS↑, Apoptosis↑, BioAv↓, *neuroP↑, *antiOx↑, *Inflam↓, *Aβ↓, *cardioP↑, MMP↓, Cyt‑c↑, MMP2↓, MMP9↓, EMT↓, MMPs↓, Twist↓, Slug↓, Ca+2↑, AIF↑, Endon↑, P-gp↓, LDH↑, HK2↓, PKA↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, GRP78/BiP↑, Casp12↑, CHOP↑,
3369- QC,    Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects
- Review, Pca, NA
FAK↓, TumCCA↑, p‑pRB↓, CDK2↑, CycB↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt↓, ROS↑, miR-21↑, Akt↓, NF-kB↓, FasL↑, Bak↑, BAX↑, Bcl-2↓, Casp3↓, Casp9↑, P53↑, p38↑, MAPK↑, Cyt‑c↑, PARP↓, CHOP↑, ROS↓, LDH↑, GRP78/BiP↑, ERK↑, MDA↓, SOD↑, GSH↑, NRF2↑, VEGF↓, PDGF↓, EGF↓, FGF↓, TNF-α↓, TGF-β↓, VEGFR2↓, EGFR↓, FGFR1↓, mTOR↓, cMyc↓, MMPs↓, LC3B-II↑, Beclin-1↑, IL1β↓, CRP↓, IL10↓, COX2↓, IL6↓, TLR4↓, Shh↓, HER2/EBBR2↓, NOTCH↓, DR5↑, HSP70/HSPA5↓, CSCs↓, angioG↓, MMP2↓, MMP9↓, IGFBP3↑, uPA↓, uPAR↓, RAS↓, Raf↓, TSP-1↑,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
66- QC,    Emerging impact of quercetin in the treatment of prostate cancer
- in-vitro, Pca, NA
CycB↓, CDK1↓, EMT↓, PI3K↓, MAPK↓, Wnt/(β-catenin)↓, PSA↓, VEGF↓, PARP↑, Casp3↑, Casp9↑, DR5↑, ROS⇅, Shh↓, P53↑, P21↑, EGFR↓,
77- QC,  EGCG,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, CD44+ - in-vitro, NA, CD133+ - in-vitro, NA, PC3 - in-vitro, NA, LNCaP
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Vim↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, TCF↓, Nanog↓,
53- QC,    Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer
- in-vitro, BC, NA
E-cadherin↑, Vim↓, cycD1↓, cMyc↓, EMT↓,
54- QC,    Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways
- in-vitro, BC, MCF-7
EMT↓, E-cadherin↑, Vim↓, MMP2↓, NOTCH1↓, PI3K/Akt↓, PI3k/Akt/mTOR↓, p‑Akt↓, EZH2↓,
56- QC,    Quercetin inhibits epithelial–mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial–mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells
- in-vitro, PC, PANC1 - in-vitro, PC, PATU-8988
EMT↓, MMPs↓, MMP2↓, MMP7↓, STAT3↓,
65- QC,    Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB
- in-vitro, BC, NA
HSP27↓, EMT↓, NF-kB↓, Snail↓, Vim↓, E-cadherin↑,
60- QC,  EGCG,  isoFl,  isoFl,  isoFl  The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓,
99- QC,    Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1
- in-vitro, Pca, PC3
EMT↓, E-cadherin↑, N-cadherin↓, Ki-67↓, PI3K/Akt↓, MALAT1↓,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
101- RES,    Resveratrol inhibits the hedgehog signaling pathway and epithelial-mesenchymal transition and suppresses gastric cancer invasion and metastasis
- in-vitro, GC, SGC-7901
HH↓, Gli1↓, EMT↓, Snail↓, N-cadherin↓, E-cadherin↑,
102- RES,    Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway
- in-vitro, PC, MIA PaCa-2
HH↓, PTCH1↓, Smo↓, HH↓, EMT↓, PI3K/Akt↓, NF-kB↓,
878- RES,    Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
- vitro+vivo, CRC, LoVo
TumMeta↓, E-cadherin↑, Vim↓, TGF-β↓, SMAD2↓, EMT↓, SMAD3↓,
1490- RES,    Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
- Review, Var, NA
TumCCA↑, ROS↑, Ca+2↑, MMP↓, ATP↓, TOP1?, P53↑, p53 Wildtype∅, Akt↓, mTOR↓, EMT↓, *BioAv↓,
3078- RES,    The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment
- Review, Pca, NA
*ROS↓, ROS↑, DNAdam↑, Apoptosis↑, Hif1a↑, Casp3↑, Casp9↑, Cyt‑c↑, Dose↝, MMPs↓, MMP2↓, MMP9↓, EMT↓, E-cadherin↑, N-cadherin↓, AR↓,
3082- RES,    Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2 - in-vivo, NA, NA
VEGF↓, CXCL12↓, IL6↓, α-SMA↓, Hif1a↓, TumCI↓, EMT↓,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF-7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3081- RES,    Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
- Review, CRC, NA
NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,
2687- RES,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, NA, NA - Review, AD, NA
NF-kB↓, P450↓, COX2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, eff↑, HK2↓, ROS↑, MMP↓,
1745- RosA,    Rosmarinic acid and its derivatives: Current insights on anticancer potential and other biomedical applications
- Review, Var, NA - Review, AD, NA
ChemoSideEff↓, ChemoSen↑, antiOx↑, MMP2↓, MMP9↓, p‑AMPK↑, DNMTs↓, tumCV↓, COX2↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, Casp3↑, Casp9↓, ROS↓, GSH↑, ERK↓, Akt↓, ROS↓, NF-kB↓, p‑IκB↓, p50↓, p65↓, neuroP↑, Dose↝,
3027- RosA,    Rosmarinic acid inhibits proliferation and invasion of hepatocellular carcinoma cells SMMC 7721 via PI3K/AKT/mTOR signal pathway
- in-vitro, HCC, SMMC-7721 cell
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, TumCMig↓, MMPs↓, Vim↓,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3003- RosA,    Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases
- Review, Var, NA - Review, AD, NA - Review, Park, NA
*Inflam↓, *antiOx↑, *neuroP↑, *IL6↓, *IL1β↓, *NF-kB↓, *PGE2↓, *COX2↓, *MMP↑, *memory↑, *ROS↓, *Aβ↓, *HMGB1↓, TumCG↓, MARK4↓, Zeb1↓, MDM2↓, BNIP3↑, ASC↑, NLRP3↓, PI3K↓, Akt↓, Casp1↓, E-cadherin↑, STAT3↓, TLR4↓, MMP↓, ICAM-1↓, AMPK↓, IL6↑, MMP2↓, Warburg↓, Bcl-xL↓, Bcl-2↓, TumCCA↑, EMT↓, TumMeta↓, mTOR↓, HSP27↓, Casp3↑, GlucoseCon↓, lactateProd↓, VEGF↓, p‑p65↓, GIT1↓, Foxm1↓, cycD1↓, CDK4↓, MMP9↓, HDAC2↓,
3006- RosA,    Rosmarinic acid attenuates glioblastoma cells and spheroids’ growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis
- in-vitro, GBM, U87MG - in-vitro, GBM, LN229
TumCG↓, EMT↓, SIRT1↓, FOXO1↓, NF-kB↓, angioG↓, ROS↓, PTEN↓, PI3K↓, Akt↓, *Inflam↓, *cardioP↑, *hepatoP↑, *neuroP↑, Warburg↓,
3037- RosA,    Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation
- in-vitro, Oral, SCC9 - in-vitro, Oral, HSC3
survivin↓, AntiCan↑, Vim↓, Snail↓, SOX9↓, EMT↓, MMP2↓, MMP9↓, P-gp↓, TumCG↓, ROS↑, MMP↓, GSH↓, P-gp↓, ATP↓,
1134- SANG,    Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
Hif1a↓, EMT↓, Snail↓, PI3K↓, Akt↓, SMAD2↓, SMAD3↓,
4485- Se,    Selenium stimulates the antitumour immunity: Insights to future research
- Review, NA, NA
*antiOx↑, chemoP↑, ROS↑, Imm↑, selenoP↑, *IL2↑, *IL4↑, *TNF-α↓, *TGF-β↓, *EMT↓, Risk↓, *GPx↑, *TrxR↑,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2↝, MMP2↝, MMP9↝,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1136- SFN,    Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells
- in-vitro, Lung, NA - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Snail↓, ERK5↑, EMT↓,
1014- SFN,    Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
Zeb1↓, Apoptosis↑, Fibronectin↓, CLDN1↓, β-catenin/ZEB1↓, EMT↓,
110- SFN,    Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway
- in-vivo, PC, NA
HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, VEGF↓, PDGFRA↓, EMT↓, Zeb1↓, Bcl-2↓, XIAP↓, E-cadherin↑, OCT4↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, *NA↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,
1138- TQ,    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoP↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoP↑, RadioS↑, *Half-Life↝, *BioAv↝,
1929- TQ,    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells
- in-vitro, Bladder, 5637 - in-vitro, Bladder, T24
tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,
3571- TQ,    The Role of Thymoquinone in Inflammatory Response in Chronic Diseases
- Review, Var, NA - Review, Stroke, NA
*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,
1139- UA,    Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells
- in-vitro, Lung, A549
TumMeta↓, AEG1↓, E-cadherin↑, N-cadherin↓, Vim↓, EMT↓,
633- VitC,    Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment
- Analysis, NA, NA
Fenton↑, ROS↑, EMT↓, DNAdam↑, PARP↑, NAD↓, ATP↓, Apoptosis↑,
1217- VitC,    High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition
- in-vitro, BC, Bcap37 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, Vim↓, EMT↓,
2366- VitD3,    Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells
- in-vitro, BC, MCF-7
Glycolysis↓, tumCV↓, Apoptosis↑, mTOR↓, AMPK↑, EMT↓, E-cadherin↑, F-actin↑, Vim↓,
1816- VitK2,    Role of Vitamin K in Selected Malignant Neoplasms in Women
- Review, Var, NA
TumCP↓, TumMeta↓, TumAuto↑, Apoptosis↑, Apoptosis↑, Casp3↑, Casp7↑, ROS↑, AR↓, EMT↓, Wnt↓, MMP↓, Cyt‑c↑, NF-kB↓, cycD1↓, TumCCA↓,
1820- VitK3,    Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1↓, TumCCA↑,
1821- VitK3,    Menadione (Vitamin K3) induces apoptosis of human oral cancer cells and reduces their metastatic potential by modulating the expression of epithelial to mesenchymal transition markers and inhibiting migration
- in-vitro, Oral, NA - in-vitro, Nor, HEK293 - in-vitro, Nor, HaCaT
selectivity↑, TumCD↓, BAX↑, P53↑, Bcl-2↓, p65↓, E-cadherin↑, EMT↓, Vim↓, Fibronectin↓, TumCG↓, TumCMig↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 196

Results for Effect on Cancer/Diseased Cells:
ACC↑,1,   ACLY↓,1,   p‑ACLY↓,1,   AEG1↓,2,   AIF↑,4,   Akt↓,51,   Akt↑,2,   p‑Akt↓,15,   AKT1↓,2,   Akt2↓,1,   ALAT↓,3,   ALDH↓,2,   ALDH1A1↓,3,   ALP↓,2,   AMPK↓,1,   AMPK↑,16,   AMPK↝,1,   p‑AMPK↑,1,   angioG↓,30,   angioG↑,2,   annexin II↓,1,   AntiAg↓,1,   AntiCan↑,7,   antiOx↑,5,   AntiTum↑,2,   AP-1↓,5,   AP-1↝,1,   APAF1↑,2,   Apoptosis↓,1,   Apoptosis↑,48,   AR↓,10,   ASC↓,1,   ASC↑,1,   AST↓,2,   ATF3↑,1,   ATF4↓,1,   ATF4↑,7,   p‑ATF4↝,1,   ATG5↑,1,   ATG7↑,1,   ATP↓,10,   mt-ATP↓,1,   AXIN1↓,1,   AXIN1↑,1,   AXL↓,2,   BAD↑,2,   Bak↑,6,   BAX↓,1,   BAX↑,27,   Bax:Bcl2↑,6,   BBB↓,1,   BBB↑,3,   Bcl-2↓,37,   Bcl-2↑,1,   Bcl-xL↓,10,   BCR-ABL↓,1,   Beclin-1↓,2,   Beclin-1↑,5,   BID↑,3,   BIM↓,1,   BIM↑,5,   BioAv↓,13,   BioAv↑,15,   BioAv↝,5,   BMP2↓,1,   BNIP3↑,2,   BOK↑,1,   BRCA1↑,1,   CA↓,1,   Ca+2↑,14,   Ca+2↝,1,   CA125↓,1,   cachexia↓,1,   CAFs/TAFs↓,2,   CAIX↓,1,   cardioP↑,6,   Casp↑,9,   Casp1↓,2,   Casp10↑,1,   Casp12↑,1,   cl‑Casp12↑,1,   cl‑Casp12↝,1,   Casp3↓,2,   Casp3↑,43,   cl‑Casp3↑,5,   Casp7↑,11,   Casp8↑,11,   cl‑Casp8↑,1,   Casp9↓,1,   Casp9↑,25,   cl‑Casp9↑,3,   proCasp9↓,1,   Catalase↓,4,   CCR7↓,1,   CD133↓,7,   CD24↓,1,   CD25+↓,1,   CD31↓,1,   CD34↓,1,   CD4+↓,1,   CD44↓,8,   CD8+↑,2,   CDC2↓,5,   CDC25↓,2,   Cdc42↓,1,   CDK1↓,6,   CDK1↑,1,   CDK2↓,18,   CDK2↑,2,   CDK4↓,22,   CDK4↑,1,   CDK6↓,9,   CDK6↑,1,   CDK8↓,1,   CDKN1C↑,1,   CDX2↓,1,   CEA↓,1,   CEBPB↓,1,   cFLIP↓,2,   cFos↓,5,   cFos↑,1,   chemoP↑,9,   ChemoSen↓,1,   ChemoSen↑,40,   ChemoSen⇅,1,   ChemoSideEff↓,3,   CHK1↓,1,   Chk2↓,1,   CHOP↑,9,   p‑CHOP↝,1,   cl‑CHOP↑,1,   CIP2A↓,1,   cJun↓,4,   cJun↑,1,   CK2↓,3,   CLDN1↓,5,   CLDN2↓,1,   cMET↓,2,   cMYB↓,1,   cMyc↓,19,   p‑cMyc↑,1,   COL1↓,1,   COL1A1↓,1,   COL3A1↓,1,   COX1↓,1,   COX2↓,34,   COX2↑,1,   COX2↝,1,   CRP↓,2,   CSCs↓,22,   CSCsMark↓,1,   cSrc↓,1,   CTNNB1↓,1,   CXCL12↓,3,   CXCR4↓,8,   cycA1↓,2,   cycA1↑,2,   CycB↓,9,   cycD1↓,33,   cycD1↑,1,   cycE↓,8,   CYP1A1↓,1,   CYP1A1↑,1,   Cyt‑c↓,1,   Cyt‑c↑,28,   DFF45↓,1,   DFF45↑,1,   Diablo↑,4,   Diff↓,2,   DNAdam↑,17,   DNMT1↓,7,   DNMT3A↓,4,   DNMTs↓,2,   Dose?,1,   Dose↓,1,   Dose↑,1,   Dose↝,6,   Dose∅,6,   DR4↑,1,   DR5↑,12,   E-cadherin↓,11,   E-cadherin↑,81,   E6↓,2,   E7↓,2,   ECAR↓,1,   EF-1α↓,1,   eff↓,4,   eff↑,69,   eff↝,5,   EGF↓,4,   EGFR↓,21,   EGFR↑,1,   p‑EGFR↓,1,   eIF2α↓,1,   eIF2α↑,2,   p‑eIF2α↑,4,   p‑eIF2α↝,1,   EM↑,2,   EMT↓,192,   Endon↑,1,   eNOS↓,2,   ENOX2↓,1,   ER Stress↑,19,   ER-α36↓,1,   ERK↓,16,   ERK↑,5,   p‑ERK↓,8,   ERK5↑,1,   EZH2↓,4,   F-actin↓,2,   F-actin↑,1,   FABP4↑,1,   FADD↑,2,   FAK↓,12,   p‑FAK↓,2,   m-FAM72A↓,1,   Fas↑,7,   FasL↑,2,   FASN↓,2,   Fenton↑,1,   Ferritin↓,1,   Ferroptosis↑,4,   FGF↓,2,   FGF↑,1,   FGFR1↓,4,   FGFR2↓,1,   Fibronectin↓,8,   FOXD3↑,1,   Foxm1↓,2,   FOXO1↓,1,   FOXO3↑,3,   p‑FOXO3↓,1,   FOXO4↓,1,   FoxP3+↓,1,   frataxin↑,1,   Galectin-9↓,1,   GIT1↓,1,   Gli↓,1,   Gli1↓,9,   GLI2↓,2,   glucoNG↓,1,   GlucoseCon↓,6,   GLUT1↓,4,   GlutMet↓,1,   Glycolysis↓,15,   GPx↓,2,   GPx4↓,2,   GREM1↓,1,   GRP78/BiP↓,1,   GRP78/BiP↑,10,   GSH↓,12,   GSH↑,3,   GSK‐3β↓,5,   GSK‐3β↑,1,   p‑GSK‐3β↓,3,   GSR↓,1,   GSR↑,1,   GSTA1↑,1,   GSTs↓,2,   GSTs↑,1,   GutMicro↑,2,   H3↓,1,   H3↑,2,   ac‑H3↑,1,   H4↓,1,   H4↑,1,   ac‑H4↑,1,   Half-Life↓,4,   Half-Life↝,4,   Half-Life∅,1,   HATs↓,1,   HATs↑,3,   HDAC↓,13,   HDAC1↓,2,   HDAC10↓,1,   HDAC2↓,2,   HDAC3↓,2,   HDAC4↓,2,   hepatoP↑,4,   HER2/EBBR2↓,5,   p‑HER2/EBBR2↓,1,   HEY1↓,1,   HGF/c-Met↓,1,   HH↓,9,   HIF-1↓,2,   Hif1a↓,34,   Hif1a↑,1,   Hif1a↝,1,   HK2↓,8,   HMG-CoA↓,1,   HMGB1↓,1,   HO-1↓,5,   HO-1↑,10,   HSF1↓,1,   HSP27↓,5,   HSP70/HSPA5↓,4,   HSP70/HSPA5↑,1,   HSP90↓,5,   hTERT↓,7,   IAP1↓,2,   IAP2↓,1,   IAP2↑,1,   ICAM-1↓,2,   IDH1↑,1,   IFN-γ↓,2,   IFN-γ↑,2,   IGF-1↓,1,   IGFBP3↓,1,   IGFBP3↑,2,   Igs↑,1,   IKKα↓,6,   IKKα↑,1,   p‑IKKα↓,1,   IL1↓,2,   IL10↓,4,   IL1β↓,8,   IL2↓,1,   IL2↑,3,   IL4↓,1,   IL6↓,19,   IL6↑,1,   IL8↓,3,   IM↓,1,   Imm↑,1,   Inflam↓,11,   iNOS↓,4,   IRE1↑,3,   Iron↑,1,   IronCh↑,1,   ITGA5↓,1,   ITGA5↑,1,   ITGB1↓,4,   ITGB1↑,1,   ITGB3↓,1,   IκB↓,1,   p‑IκB↓,1,   JAK↓,1,   p‑JAK↓,1,   JAK1↓,1,   JAK2↓,5,   p‑JAK2↓,2,   p‑JAK3↓,1,   JNK↑,8,   p‑JNK↓,1,   p‑JNK↑,1,   Keap1↑,1,   Ki-67↓,13,   lactateProd↓,8,   LAMA5↑,1,   LAMs↓,2,   LC3‑Ⅱ/LC3‑Ⅰ↓,1,   LC3B-II↑,2,   LC3II↓,2,   LC3II↑,8,   LDH↓,4,   LDH↑,2,   LDHA↓,3,   LDL↓,1,   LEF1↓,3,   Let-7↑,2,   lipid-P↓,2,   lipid-P↑,4,   M2 MC↓,1,   MAD↓,1,   MALAT1↓,4,   MAOA↓,1,   MAPK↓,15,   MAPK↑,8,   MARK4↓,1,   Maspin↑,1,   Mcl-1↓,12,   Mcl-1↑,1,   MCP1↓,1,   MDA↓,1,   MDA↑,3,   MDM2↓,4,   p‑MDM2↓,1,   MDR1↓,3,   MDSCs↓,1,   MEK↓,3,   MET↓,2,   MET↑,1,   p‑MET↓,1,   MGMT↓,1,   miR-141↑,1,   miR-145↑,1,   miR-200c↑,1,   miR-203↑,1,   miR-21↓,1,   miR-21↑,1,   miR-27a-3p↓,1,   miR-301a-3p↓,1,   miR-34a↑,2,   mitResp↓,2,   MKK4↓,1,   MMP↓,33,   MMP↑,1,   MMP-10↓,2,   MMP1↓,2,   MMP13↓,1,   MMP2↓,58,   MMP2↝,1,   MMP3↓,2,   MMP7↓,7,   MMP9↓,59,   MMP9↑,1,   MMP9↝,1,   MMPs↓,16,   Mortalin↓,1,   MSCmark↓,1,   mtDam↑,4,   mTOR↓,36,   mTOR↝,1,   p‑mTOR↓,4,   mTORC1↓,3,   p‑mTORC1↓,1,   mTORC2↓,1,   MUC1↑,1,   MUC4↓,1,   Myc↓,2,   N-cadherin↓,49,   n-MYC↓,1,   NA↓,1,   NA↑,2,   NAD↓,1,   NADPH↓,4,   NADPH↑,1,   NAIP↓,1,   Nanog↓,11,   NDRG1↑,1,   Necroptosis↑,1,   Nestin↓,3,   neuroP↑,5,   NF-kB↓,61,   NF-kB↑,1,   p‑NF-kB↓,1,   p‑NF-kB↑,2,   NHE1↓,1,   NICD↓,1,   NKD2↑,1,   NLRP3↓,2,   NO↓,1,   NO↑,1,   NO↝,1,   NOTCH↓,10,   NOTCH1↓,9,   NOTCH1↑,3,   NOTCH1↝,1,   NOTCH3↓,2,   NOXA↑,1,   NQO1↓,1,   NQO1↑,4,   NRF2↓,12,   NRF2↑,11,   NSE↓,1,   OCR↓,3,   OCT4↓,8,   OS↑,5,   other↓,1,   OXPHOS↓,1,   OXPHOS↑,1,   mt-OXPHOS↓,1,   P-gp↓,7,   p16↑,2,   P21?,1,   P21↓,1,   P21↑,18,   p27↑,7,   p300↓,1,   p38↓,3,   p38↑,8,   p‑p38↓,2,   p‑p38↑,1,   P450↓,3,   p50↓,1,   P53?,1,   P53↑,31,   ac‑P53↑,1,   p53 Wildtype∅,1,   p62↓,3,   p62↑,1,   p65↓,4,   p65↑,1,   p‑p65↓,4,   p70S6↓,1,   P70S6K↓,2,   P90RSK↓,2,   PARP↓,1,   PARP↑,7,   cl‑PARP↑,17,   PARP1↑,1,   p‑pax↓,1,   PCNA↓,11,   PD-1↓,4,   PD-L1↓,6,   PD-L2↓,1,   PDGF↓,4,   PDGFR-BB↓,1,   PDGFRA↓,1,   PDH↝,1,   PDK1↓,4,   p‑PDK1↓,2,   PDK3↑,1,   PERK↑,4,   p‑PERK↝,1,   PFK↓,1,   PGE2↓,12,   PI3K↓,46,   p‑PI3K↓,4,   PI3K/Akt↓,4,   PI3k/Akt/mTOR↓,1,   PIR↓,1,   Pirin↓,1,   PKA↓,1,   PKCδ↓,4,   PKM2↓,12,   POLD1↓,1,   PPARα↓,1,   PPARα↑,1,   PPARα↝,1,   PPARγ↓,1,   PPARγ↑,2,   pRB↓,1,   p‑pRB↓,1,   PSA↓,2,   PTCH1↓,3,   PTCH2↓,1,   PTEN↓,2,   PTEN↑,12,   PUMA↑,1,   PYCR1↓,1,   Rac1↓,2,   radioP↑,1,   RadioS↑,21,   Raf↓,4,   c-Raf↓,1,   RAGE↓,1,   RARα↓,1,   RARβ↑,1,   RARγ↑,1,   RAS↓,3,   RB1↓,1,   RB1↑,1,   p‑RB1↓,3,   RenoP↑,3,   RET↓,1,   RHBDD1↓,1,   Rho↓,4,   RIP1↑,1,   RIP3↑,1,   Risk↓,1,   ROCK1↓,4,   ROS↓,17,   ROS↑,74,   ROS⇅,4,   mt-ROS↑,2,   p‑S6K↓,1,   selectivity↑,19,   selenoP↑,1,   SFRP5↑,1,   Shh↓,9,   SHP1↑,1,   SIRT1↓,8,   SIRT1↑,3,   SIRT2↓,1,   SIRT3↓,1,   SIRT3↑,4,   SIRT6↓,1,   Slug↓,22,   SMAD2↓,4,   p‑SMAD2↓,10,   SMAD3↓,6,   p‑SMAD3↓,8,   SMAD4↓,1,   Smo↓,4,   Snail?,1,   Snail↓,44,   Snail↑,1,   SOD↓,7,   SOD↑,2,   SOD1↓,1,   SOD1↑,1,   SOD2↓,2,   SOD2↑,1,   SOX2↓,6,   SOX4↓,1,   SOX9?,1,   SOX9↓,1,   Sp1/3/4↓,10,   Src↓,2,   p‑Src↓,1,   SREBP1↓,1,   STAC2↓,1,   STAT↓,1,   p‑STAT1↓,1,   p‑STAT2↓,1,   STAT3↓,35,   p‑STAT3↓,8,   p‑STAT3↑,1,   STAT6↓,1,   p‑STAT6↓,1,   Sufu↓,1,   survivin↓,22,   Symptoms∅,1,   T-Cell↑,1,   TAZ↓,1,   TCA↓,1,   TCF↓,4,   TCF-4↓,2,   Telomerase↓,6,   TET1↓,1,   TET1↑,3,   TGF-β↓,23,   TGF-β↑,1,   Th1 response↑,1,   TILs↑,1,   TIM-3↓,1,   TIMP1↑,4,   TIMP2↑,1,   TLR4↓,3,   TNF-α↓,10,   TNFR 1↑,1,   TOP1?,1,   TOP1↓,6,   TOP2↓,3,   TOPflash↓,1,   toxicity?,1,   toxicity↓,1,   toxicity↑,1,   toxicity↝,1,   toxicity∅,1,   TP53↑,2,   TRAIL↑,1,   TRAILR↑,2,   Trx1↑,1,   TrxR↓,1,   TSC2↑,1,   TSP-1↑,4,   TumAuto↑,9,   TumCA↓,1,   TumCCA↓,2,   TumCCA↑,56,   TumCD↓,1,   TumCD↑,1,   TumCG↓,24,   TumCI↓,54,   TumCMig↓,57,   TumCMig↑,1,   TumCP↓,42,   tumCV↓,13,   TumMeta↓,36,   TumVol↓,5,   TumW↓,4,   Twist↓,22,   Tyro3↓,1,   tyrosinase↓,1,   uPA↓,20,   uPAR↓,1,   UPR↑,2,   VEGF↓,53,   VEGFR2↓,10,   Vim?,1,   Vim↓,64,   Vim↑,2,   VitC↓,1,   VitE↓,1,   Warburg↓,4,   Wnt↓,19,   Wnt/(β-catenin)↓,5,   XBP-1↓,1,   XIAP↓,15,   YAP/TEAD↓,2,   ZBTB10↑,1,   Zeb1↓,22,   Zeb1↑,1,   ZEB2↓,1,   ZEB2↑,1,   ZO-1↓,1,   ZO-1↑,5,   α-SMA↓,3,   α-SMA↑,1,   α-tubulin↓,1,   β-catenin/ZEB1↓,37,   β-catenin/ZEB1↑,1,   p‑β-catenin/ZEB1↓,1,   γH2AX↑,2,  
Total Targets: 686

Results for Effect on Normal Cells:
AChE↓,1,   Akt↓,1,   Akt↑,1,   ALAT↓,1,   AMPK↑,1,   angioG↑,1,   AntiCan↑,1,   antiOx↓,1,   antiOx↑,20,   AST↓,2,   Aβ↓,4,   BACE↓,1,   BBB↑,2,   Beclin-1↓,1,   BioAv↓,17,   BioAv↑,2,   BioAv↝,3,   cardioP↑,7,   Casp3?,1,   Casp3↓,1,   Catalase↑,8,   chemoP↑,2,   p‑cMyc↑,1,   cognitive↑,3,   COL1↓,2,   COL3A1↓,1,   COX2↓,6,   CRP↓,1,   Dose↑,1,   E-cadherin↑,3,   eff↑,3,   EMT↓,5,   ERK↑,1,   p‑ERK↓,1,   Fibronectin↓,1,   GPx↓,1,   GPx↑,5,   GSH↑,11,   GSR↑,2,   GSTA1↑,1,   GSTs↑,5,   Half-Life↝,5,   Half-Life∅,1,   HDAC↓,1,   HDAC3↓,1,   HDL↑,1,   hepatoP↑,7,   Hif1a↓,1,   HMGB1↓,1,   HO-1↑,1,   IFN-γ↓,1,   IFN-γ↑,1,   IL10↓,1,   IL10↑,1,   IL18↓,1,   IL1β↓,8,   IL2↓,1,   IL2↑,1,   IL4↑,1,   IL5↓,1,   IL6↓,6,   IL8↓,3,   Inflam↓,17,   iNOS↓,2,   IRF3↓,1,   IronCh↑,1,   JNK↑,1,   Keap1↓,1,   Ki-67↓,1,   LDHA↑,1,   lipid-P↓,4,   lipidLev↓,1,   MAPK↓,1,   MDA↓,4,   memory↑,3,   MMP↑,2,   MMP13↓,2,   MMP2↓,1,   MMP9↓,1,   motorD↑,1,   MPO↓,2,   MyD88↓,1,   NA↓,1,   NAD↑,1,   neuroP↑,14,   NF-kB↓,5,   NO↓,2,   NO↑,1,   NRF2↑,7,   P450↓,1,   p‑P70S6K↓,1,   PGE2↓,4,   PI3K↓,1,   PI3K↑,1,   PKM2↓,1,   p‑PPARγ↓,1,   Prx↑,1,   PTEN↑,1,   radioP↑,1,   RenoP↑,4,   ROS↓,23,   Sepsis↓,1,   SIRT1↑,3,   Smad7↑,2,   SOD↑,9,   SOD2↑,1,   TAC↑,1,   p‑tau↓,1,   TGF-β↓,3,   TGF-β1↓,1,   TIMP1↓,1,   TLR2↓,1,   TLR4↓,2,   TNF-α↓,8,   toxicity↓,10,   toxicity↝,1,   toxicity∅,2,   TrxR↑,1,   uricA↓,1,   VEGF↑,1,   Vim↓,3,   α-SMA↓,5,   β-catenin/ZEB1↓,1,  
Total Targets: 123

Scientific Paper Hit Count for: EMT, Epithelial-Mesenchymal Transition
15 Curcumin
12 Quercetin
11 Resveratrol
10 Honokiol
9 Sulforaphane (mainly Broccoli)
9 Thymoquinone
8 Fisetin
6 Ashwagandha
6 Metformin
6 Rosmarinic acid
5 Apigenin (mainly Parsley)
5 Betulinic acid
5 Chrysin
5 EGCG (Epigallocatechin Gallate)
5 Luteolin
5 Piperine
5 Silymarin (Milk Thistle) silibinin
4 Alpha-Lipoic-Acid
4 Berberine
4 Propolis -bee glue
3 Artemisinin
3 Baicalein
3 Emodin
3 Ferulic acid
3 Piperlongumine
3 isoflavones
3 Shikonin
2 Ellagic acid
2 Genistein
2 Fucoidan
2 Garcinol
2 Grapeseed extract
2 Lycopene
2 Naringin
2 Vitamin C (Ascorbic Acid)
2 VitK3,menadione
1 Anthocyanins
1 Allicin (mainly Garlic)
1 Astragalus
1 Baicalin
1 Biochanin A
1 Boron
1 Caffeic acid
1 Capsaicin
1 Cannabidiol
1 Celecoxib
1 Cyclopamine
1 5-fluorouracil
1 Oxaliplatin
1 Deguelin
1 Docosahexaenoic Acid
1 Evodiamine
1 Shilajit/Fulvic Acid
1 Gallic acid
1 Paclitaxel
1 Proanthocyanidins
1 Hydroxycinnamic-acid
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Licorice
1 Lactoferrin
1 methotrexate
1 Magnolol
1 Myricetin
1 Pterostilbene
1 Sanguinarine
1 Selenium
1 statins
1 Citric Acid
1 Ursolic acid
1 Vitamin D3
1 Vitamin K2
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:96  State#:0  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page